Melanoma, the cancer's mutational signature may change the treatment
Researchers presented results from the Phase 3 INTerpath-001 study at the 2026 European Society for Medical Oncology conference in Madrid, highlighting a new personalized therapeutic vaccine for melanoma. The experimental treatment, known as intismeran autogene, utilizes mRNA technology to target specific tumor neoantigens identified through a patient's unique mutational signature. Developed jointly by Merck Sharp Dohme (Msd) and Moderna, the therapy was tested in combination with the existing drug pembrolizumab for patients with stage IIB-IV melanoma who had undergone complete surgical removal. Data showed that adding intismeran to pembrolizumab reduced the risk of recurrence or death by 42 percent compared to using pembrolizumab alone after a median follow-up period of 24.6 months. Additionally, the combined approach lowered the risk of distant metastasis or death by 38 percent overall, with sensitivity analyses indicating a 58 percent reduction in recurrence risk starting six months into the treatment regimen. These findings were accepted for publication in The New England Journal of Medicine and suggest a potential shift toward personalized immune-based therapies for early-to-m
A personalized therapeutic vaccine based on messenger RNA technology has demonstrated efficacy against melanoma, reducing the risk of disease recurrence by 42 percent over two years when added to standard immunotherapy. These findings from the phase three clinical trial INTerpath-001 were presented at the Congress of the European Society for Medical Oncology in Madrid. The results mark the first time a fully customized therapeutic vaccine has shown benefit in a phase three study. The data are scheduled for publication in the New England Journal of Medicine this November. The trial enrolled 1,137 patients with high-risk melanoma who had undergone complete surgical removal of their tumors. Participants were treated across 157 centers worldwide. Italy contributed the highest number of patients among all countries involved in the study. The treatment regimen combined the vaccine, known as intismeran autogene, with pembrolizumab, an immune checkpoint inhibitor developed by Merck Sharp & Dohme. The vaccine was developed jointly by MSD and Moderna. Patients received nine doses of the vaccine over a period of one year. After a median follow-up of 24.6 months, the combination therapy reduced the risk of recurrence or death by 42 percent compared to pembrolizumab alone. It also lowered the risk of distant metastasis or death by 38 percent. An analysis conducted after the initial six-month immunization period showed even greater benefits. From month six onward, adding the vaccine to pembrolizumab reduced the risk of recurrence or death by 58 percent and halved the risk of distant metastasis or death. During the first six months of treatment, the efficacy of the combination was comparable to that of pembrolizumab alone. The vaccine is designed specifically for each patient’s unique tumor profile. Researchers sequence the DNA of the removed tumor tissue to identify mutations. They then synthesize mRNA in a laboratory to encode up to 34 neoantigens, which are mutated proteins exclusive to that individual’s cancer cells. Once injected, these instructions direct the patient’s cells to produce the neoantigens. This process presents a detailed biological signature of the tumor to the immune system, enabling it to recognize and destroy residual cancer cells circulating in the body. The goal is to prevent recurrence by strengthening the immune response against specific targets left behind after surgery. Michele Del Vecchio, head of medical oncology for melanomas at the National Cancer Institute in Milan, stated that INTerpath-001 is the first and only phase three study demonstrating superior results with the combination of mRNA vaccine and immunotherapy compared to standard care. He noted that the new combination showed good tolerability without an increase in side effects relative to immunotherapy alone. The Italian center led by Del Vecchio recruited 82 patients, making it the site with the largest enrollment globally. Paola Queirolo, coordinator of the melanoma network at the Metropolitan Hospital of Genoa, explained that the vaccine is therapeutic rather than preventive. It is administered after surgery to further boost the immune system against the specific molecular characteristics of the patient’s tumor. Georgina Long, the principal investigator of the study and director of the Melanoma Institute in Australia, described the results as transformative. She said the findings support a radically new approach to adjuvant treatment that adapts therapy to the unique mutational signature of each patient’s tumor. For decades, oncological treatments have been largely defined by the anatomical origin of the cancer. Long indicated that while these results apply to stage IIB through IV completely resected melanoma, they provide valuable insights as clinical research continues in other tumor types and settings. In Italy, approximately 13,000 new cases of melanoma are diagnosed annually. About 5,000 of these patients would be candidates for this type of therapy. The preparation of the personalized vaccine requires a complex organizational effort involving oncologists, surgeons, pathologists, molecular biologists, and pharmacists. The process involves analyzing adequate tumor samples, selecting neoantigens, and producing the final product, which takes approximately six weeks. The vaccine is not yet available for general use. Regulatory agencies including the US Food and Drug Administration, the European Medicines Agency, and the Italian Medicines Agency are currently reviewing the application. In the interim, authorities will consider activating special access programs for patients. While the cost of the personalized vaccine remains high, efforts are underway to reduce prices to ensure accessibility and sustainability. Research teams are already applying the same principle to develop mRNA vaccines for other cancers, including lung, pancreatic, and genitourinary tumors. The success of this trial provides a foundation for expanding this personalized approach beyond melanoma.
A fully personalized mRNA therapeutic vaccine has demonstrated efficacy against melanoma in a Phase 3 clinical trial, reducing the risk of disease recurrence by 42 percent when added to standard immunotherapy over two years. The results of the INTerpath-001 study were presented at the European Society for Medical Oncology congress and are scheduled for publication in the New England Journal of Medicine. The trial involved 1,137 high-risk patients across 157 global centers, with Italy contributing the highest number of enrolled participants. The vaccine, known as mRNA-4157, is custom-manufactured based on the unique DNA mutations of an individual patient’s tumor to stimulate an immune response against residual cancer cells. Italian oncologists noted that approximately 5,000 patients annually could potentially benefit from this therapy, which showed good tolerability without increased side effects compared to immunotherapy alone.
Bias read (Center): The article reports on medical research findings regarding a new cancer treatment. It cites scientific data, clinical trial results, and expert opinions from oncologists. There is no political controversy, partisan framing, or ideological debate associated with the subject matter, making it apolitic
Why factuality (95): The article accurately reflects the core findings of the INTerpath-001 study presented at ESMO, including the 42% reduction in recurrence risk and the involvement of 1,137 patients. It correctly identifies the mechanism (mRNA-based personalized vaccine targeting neoantigens) and the combination ther
Why objectivity (95): The tone is informative and professional, typical of a wire service report. It presents the scientific breakthrough neutrally without excessive hype or emotional language, focusing on the clinical data and implications.
Il GiornaleParty-alignedCenterFactual: no official source document/info detectedObjective 95
A Phase 3 clinical trial named INTerpath-001 has demonstrated that a personalized therapeutic mRNA vaccine significantly reduces cancer recurrence risks in patients with high-risk melanoma. The study involved 1,137 patients who had undergone radical surgery and were treated with either the vaccine combined with pembrolizumab or pembrolizumab alone. Results presented at the European Society for Medical Oncology conference in Madrid showed that adding the vaccine reduced the risk of recurrence by 42 percent and distant metastasis by 38 percent compared to the standard immunotherapy alone. The treatment was well-tolerated, with no significant increase in side effects observed in the combination group. This marks the first time an individualized neoantigen therapy has shown benefit in a Phase 3 trial, potentially changing the standard of care for this condition.
Bias read (Center): The article reports on medical research findings regarding a new cancer treatment. It cites specific clinical data and expert commentary from an Italian oncologist but does not engage in political debate, policy advocacy, or partisan framing. The content is strictly scientific and informational.
Why factuality: no official source document/info detected
Why objectivity (95): Neutral and balanced reporting. Uses direct quotes to convey enthusiasm rather than injecting editorial opinion. Clearly distinguishes between the new therapy and current standards, providing context without bias.
Il GiornaleParty-alignedCenterFactual: no official source document/info detectedObjective 90
Researchers presented results from the Phase 3 INTerpath-001 study at the 2026 European Society for Medical Oncology conference in Madrid, highlighting a new personalized therapeutic vaccine for melanoma. The experimental treatment, known as intismeran autogene, utilizes mRNA technology to target specific tumor neoantigens identified through a patient's unique mutational signature. Developed jointly by Merck Sharp Dohme (Msd) and Moderna, the therapy was tested in combination with the existing drug pembrolizumab for patients with stage IIB-IV melanoma who had undergone complete surgical removal. Data showed that adding intismeran to pembrolizumab reduced the risk of recurrence or death by 42 percent compared to using pembrolizumab alone after a median follow-up period of 24.6 months. Additionally, the combined approach lowered the risk of distant metastasis or death by 38 percent overall, with sensitivity analyses indicating a 58 percent reduction in recurrence risk starting six months into the treatment regimen. These findings were accepted for publication in The New England Journal of Medicine and suggest a potential shift toward personalized immune-based therapies for early-to-m
Bias read (Center): The article reports on medical research and clinical trial results regarding cancer treatment. It focuses on scientific data, pharmaceutical development, and expert commentary on efficacy metrics. There is no political controversy, partisan framing, or ideological debate involved in the subject or d
Why factuality: no official source document/info detected
Why objectivity (90): While largely objective, the headline uses slightly promotional language ('potrà cambiare la cura'), though this is common in medical journalism covering major breakthroughs. The body text remains balanced and cites specific data points clearly.
How each side covered it
The same event, grouped by the political lean of the outlets covering it.
progressive
center
conservative
★
How each side covered it
Support independent, bias-aware news and unlock the social pulse, community voting, and every other Supporter feature.
Italy
